A Phase 2 interventional study of Rimegepant and Placebo in Trigeminal Neuralgia, sponsored by Pfizer. Terminated at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-10.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Trigeminal Neuralgia with a site in United States — 7 open to participants now, 11 under way, 1 of them phase 3. Trigeminal Neuralgia · United States.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 2, and was the 21st registered.
140 studies on the registry are indexed under Trigeminal Neuralgia; 44 are open to participants now.
Browse Trigeminal Neuralgia studies →7 of the 34 studies in Trigeminal Neuralgia with a site in United States are open now. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The Foundation for Orthopaedics and Regenerative Medicine · Sites in United States, Greece
University of Minnesota · Sites in United States
Ages 18+ · Healthy volunteers
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Trigeminal Neuralgia studies recruiting now, 18 (67%) set no upper age limit and 3 (11%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 3
First in 1997; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is above the median of 40 across 93 interventional studies indexed under Trigeminal Neuralgia.
Median enrollment 29 across the 26 interventional studies, 56 across the 8 observational. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 34 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Trigeminal Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Trigeminal Neuralgia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05217628Phase 3Noema Pharma AGAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | 2027-02-02 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT06216886Stanford UniversityOnabotulinumtoxinA for Trigeminal Neuralgia | 2027-02-01 |
| NCT05269472University of MinnesotaTrigeminal Neuralgia Electrophysiology | 2027-11-01 |
| NCT05738096University of MinnesotaTrigeminal Evoked Responses to Improve Rhizotomy | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 34 studies in Trigeminal Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of BHV3000 compared to placebo for subjects with treatment refractory Trigeminal Neuralgia as measured by a 2-point or greater reduction in the average Numeric Pain Rating Scale between the two-week treatment phases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rimegepant
Drug: Placebo
BHV3000 (rimegepant) 75mg tablet
Placebo
Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period on NPRS. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.
Time frame: DBT Phase: Baseline (before dose on Day 1), 2 Weeks Treatment
Number of Participants With All-Causality Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Study Drug Discontinuation and Treatment Related AEs: DBT Phase
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect other important medical events. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to drug was assessed by investigator.
Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase
S-STS is a scale that assesses the seriousness of suicidality phenomena on a 5-point Likert-type scale (0 to 4) ranging from "not at all" (0) to "extremely" (4), where higher scores signify suicidal tendency. In this outcome measure, number of participants who had any change in S-STS score from baseline to end of treatment are reported according to the treatment received in first or second treatment period of DBT phase.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase
ECG abnormalities included were a Corrected QT interval exceeding 470 milliseconds (QTc calculated using the Frederica method), left bundle branch block, right bundle branch block with a QRS duration of 150 milliseconds or more, and intraventricular conduction defect with a QRS duration equal to or greater than 150 milliseconds. Clinical significance in ECG abnormalities was judged by investigator.
Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase
Laboratory abnormalities included 1)Hematology: hemoglobin, hematocrit, platelets, complete blood count with differential and absolute neutrophil count; 2)Serum chemistry: sodium, potassium, chloride, calcium, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase, phosphorus, bicarbonate, creatine phosphokinase, total protein, albumin, total bilirubin, glucose, creatinine, blood urea nitrogen, uric acid, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, folate, hemoglobin A1C, pancreatic amylase or lipase, thyroid-stimulating Hormone, thyroxine; 3)Urinalysis: macroscopic examination, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, protein, glucose, occult blood; 4)Liver function tests: alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. Clinical significance in laboratory abnormalities was judged by investigator.
Time frame: DBT Phase: Day 1 of dosing up to last day of dosing (up to 5 weeks)
Change From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase
Penn-FPS-R: a 12-item scale, utilized to evaluate the impact of TN pain on health-related quality of life and daily activities. Each 12 items ranged from 0 (does not interfere) to 10 (completely interferes). Penn-FPS-R total score was calculated by adding scores of all items and had a score range of (does not interfere) 0 to 120 (completely interferes).Higher Penn-FPS-R total scores signifies worse condition. Participants were asked to complete the Penn-FPS-R at the beginning and end of each treatment period. Average of total Penn-FPS-score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
Change From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase
Pain disability index measures the extent of disruption in a participant's daily life caused by pain, utilizing a 7-item scale scored on an 11-point Likert Scale, where "0" denotes "no disability," and "10" indicates "worst disability". Higher scores signify worse outcome. Pain disability index total score was calculated by adding scores of all the 7 items and had a score range of 0 to 70. Higher pain disability index total scores signifies worse condition. Participants were instructed to complete the pain disability index at the beginning and end of each treatment period. Average of pain disability index total scores according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
Patient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase
PGI-C is a participant-reported scale utilized to evaluate the improvement or deterioration of the participant's current illness status compared to the baseline visit. Participants were asked to rate a change in their overall disease condition on a 7-point scale, ranging from 1 (no change) to 7 (a great deal better). Higher PGI-C scores signify better outcome. PGI-C assessments were conducted at the beginning and end of each treatment phase. Average of PGI-C score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
Change From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their worst pain rating over a 24-hour period on NPRS. Average of worst pain NPRS score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
Percentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT Phase are used in evaluation of the outcome measure.
Time frame: DBT Phase: Baseline, 2 Weeks Treatment
There were 2 phases in the study: double blind treatment (DBT) phase followed by open label extension (OLE) phase. Participants after completing DBT phase could enter OLE phase if the Principal Investigator (PI) believed open-label treatment offered an acceptable risk-benefit profile. A total of 65 participants with refractory trigeminal neuralgia (TN) were enrolled in the study.
| Milestone | DBT Phase: Placebo Then Rimegepant (BHV-3000) | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant |
|---|---|---|---|
| Started | 15 | 15 | 0 |
| Treated | 15 | 14 | 0 |
| Completed | 14 | 14 | 0 |
| Not completed | 1 | 1 | 0 |
| Withdrew: Randomized but not treated | 0 | 1 | 0 |
| Withdrew: Non compliance | 1 | 0 | 0 |
| Milestone | DBT Phase: Placebo Then Rimegepant (BHV-3000) | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant |
|---|---|---|---|
| Started | 14 | 14 | 0 |
| Completed | 14 | 14 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | DBT Phase: Placebo Then Rimegepant (BHV-3000) | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant |
|---|---|---|---|
| Started | 14 | 14 | 0 |
| Completed | 14 | 14 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | DBT Phase: Placebo Then Rimegepant (BHV-3000) | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant |
|---|---|---|---|
| Started | 0 | 0 | 13 |
| Completed | 0 | 0 | 9 |
| Not completed | 0 | 0 | 4 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 |
| Withdrew: Sponsor decision | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period on NPRS. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.
| Units on a scale | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Change From Baseline in the Average Daily Pain Score on Numeric Pain Rating Scale (NPRS) at 2 Week Treatment Phase: DBT Phase | -.5 (-1.1 to -.1) | -1.2 (-1.8 to -0.6) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect other important medical events. A treatment-related AE was any untoward medical occurrence attributed to the study drug in a participant who received study drug. Relatedness to drug was assessed by investigator.
| Participants | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| SAEs | 0 | 0 |
| AEs Leading to Study Drug Discontinuation | 0 | 0 |
| Treatment Related AEs | 4 | 0 |
S-STS is a scale that assesses the seriousness of suicidality phenomena on a 5-point Likert-type scale (0 to 4) ranging from "not at all" (0) to "extremely" (4), where higher scores signify suicidal tendency. In this outcome measure, number of participants who had any change in S-STS score from baseline to end of treatment are reported according to the treatment received in first or second treatment period of DBT phase.
| Participants | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Number of Participants With Any Change From Baseline in Sheehan Suicidality Tracking Scale (S-STS) Scores: DBT Phase | 0 | 0 |
ECG abnormalities included were a Corrected QT interval exceeding 470 milliseconds (QTc calculated using the Frederica method), left bundle branch block, right bundle branch block with a QRS duration of 150 milliseconds or more, and intraventricular conduction defect with a QRS duration equal to or greater than 150 milliseconds. Clinical significance in ECG abnormalities was judged by investigator.
| Participants | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities: DBT Phase | 0 | 0 |
Laboratory abnormalities included 1)Hematology: hemoglobin, hematocrit, platelets, complete blood count with differential and absolute neutrophil count; 2)Serum chemistry: sodium, potassium, chloride, calcium, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase, gamma-glutamyl transferase, phosphorus, bicarbonate, creatine phosphokinase, total protein, albumin, total bilirubin, glucose, creatinine, blood urea nitrogen, uric acid, total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides, folate, hemoglobin A1C, pancreatic amylase or lipase, thyroid-stimulating Hormone, thyroxine; 3)Urinalysis: macroscopic examination, pH, specific gravity, ketones, nitrites, urobilinogen, leukocyte esterase, protein, glucose, occult blood; 4)Liver function tests: alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase. Clinical significance in laboratory abnormalities was judged by investigator.
| Participants | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Number of Participants With Clinically Significant Laboratory Abnormalities: DBT Phase | 0 | 0 |
Penn-FPS-R: a 12-item scale, utilized to evaluate the impact of TN pain on health-related quality of life and daily activities. Each 12 items ranged from 0 (does not interfere) to 10 (completely interferes). Penn-FPS-R total score was calculated by adding scores of all items and had a score range of (does not interfere) 0 to 120 (completely interferes).Higher Penn-FPS-R total scores signifies worse condition. Participants were asked to complete the Penn-FPS-R at the beginning and end of each treatment period. Average of total Penn-FPS-score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
| Units on a scale | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Change From Baseline in Penn Facial Pain Scale-Revised (Penn-FPS-R) Total Score at 2 Week Treatment Phase: DBT Phase | -14.2 (-22.2 to -6.2) | -16.6 (-24.6 to -8.6) |
Pain disability index measures the extent of disruption in a participant's daily life caused by pain, utilizing a 7-item scale scored on an 11-point Likert Scale, where "0" denotes "no disability," and "10" indicates "worst disability". Higher scores signify worse outcome. Pain disability index total score was calculated by adding scores of all the 7 items and had a score range of 0 to 70. Higher pain disability index total scores signifies worse condition. Participants were instructed to complete the pain disability index at the beginning and end of each treatment period. Average of pain disability index total scores according to treatment received in first or second treatment period of DBT phase are used for evaluation of the outcome measure.
| Units on a scale | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Change From Baseline in Pain Disability Index Total Score at 2 Week Treatment Phase: DBT Phase | -7.8 (-12.6 to -2.9) | -9.3 (-14.2 to -4.5) |
PGI-C is a participant-reported scale utilized to evaluate the improvement or deterioration of the participant's current illness status compared to the baseline visit. Participants were asked to rate a change in their overall disease condition on a 7-point scale, ranging from 1 (no change) to 7 (a great deal better). Higher PGI-C scores signify better outcome. PGI-C assessments were conducted at the beginning and end of each treatment phase. Average of PGI-C score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
| Units on a scale | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Patient Global Impression of Change Scale (PGI-C) Score at 2 Week Treatment Phase: DBT Phase | 3.0 (2.3 to 3.8) | 3.1 (2.4 to 3.8) |
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their worst pain rating over a 24-hour period on NPRS. Average of worst pain NPRS score according to treatment received in first or second treatment period of DBT phase are used in evaluation of the outcome measure.
| Units on a scale | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Change From Baseline in Average Worst Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase | -0.6 (-1.3 to 0.1) | -1.3 (-2.0 to -0.6) |
NPRS is an 11-point scale ranging from 0 (no pain) to 10 (worst pain imaginable), higher scores represent worse pain. Participants daily recorded their average pain level over a 24-hour period. Pain score was the average of the daily 11-point NPRS recorded within each period. Average of pain score on NPRS according to treatment received in first or second treatment period of DBT Phase are used in evaluation of the outcome measure.
| Percentage of participants | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo |
|---|---|---|
| Percentage of Participants With >= 2 Point Reduction From Baseline in Average Daily Pain Score on NPRS at 2 Week Treatment Phase: DBT Phase | 10.7 | 35.7 |
Collected over Day 1 up to 2 weeks of follow up post-last dose in the study (Maximum up to 19 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBT Phase/ Treatment Sequence 1/ Period 1: Placebo | 0/15 (0%) | 0/15 (0%) | 1/15 (6.7%) |
| DBT Phase/ Treatment Sequence 1/ Period 2: Rimegepant | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| DBT Phase/ Treatment Sequence 2/ Period 1: Rimegepant | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| DBT Phase/ Treatment Sequence 2/ Period 2: Placebo | 0/14 (0%) | 0/14 (0%) | 0/14 (0%) |
| DBT Phase: Pooled Rimegepant | 0/28 (0%) | 0/28 (0%) | 6/28 (21.4%) |
| DBT Phase: Pooled Placebo | 0/29 (0%) | 0/29 (0%) | 1/29 (3.4%) |
| OLE Phase: Rimegepant | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Event | DBT Phase/ Treatment Sequence 1/ Period 1: Placebo | DBT Phase/ Treatment Sequence 1/ Period 2: Rimegepant | DBT Phase/ Treatment Sequence 2/ Period 1: Rimegepant | DBT Phase/ Treatment Sequence 2/ Period 2: Placebo | DBT Phase: Pooled Rimegepant | DBT Phase: Pooled Placebo | OLE Phase: Rimegepant |
|---|---|---|---|---|---|---|---|
| Trigeminal neuralgiaNervous system disorders | 0/15 | 1/14 | 2/14 | 0/14 | 3/28 | 0/29 | 3/13 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/15 | 0/14 | 0/14 | 0/14 | 0/28 | 0/29 | 1/13 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/15 | 0/14 | 0/14 | 0/14 | 0/28 | 0/29 | 1/13 |
| FallInjury, poisoning and procedural complications | 0/15 | 0/14 | 0/14 | 0/14 | 0/28 | 0/29 | 1/13 |
| Abdominal painGastrointestinal disorders | 0/15 | 1/14 | 0/14 | 0/14 | 1/28 | 0/29 | 0/13 |
| Abdominal tendernessGastrointestinal disorders | 0/15 | 1/14 | 0/14 | 0/14 | 1/28 | 0/29 | 0/13 |
| DizzinessNervous system disorders | 0/15 | 0/14 | 1/14 | 0/14 | 1/28 | 0/29 | 0/13 |
| COVID-19Infections and infestations | 0/15 | 0/14 | 1/14 | 0/14 | 1/28 | 0/29 | 0/13 |
| DepressionPsychiatric disorders | 0/15 | 1/14 | 0/14 | 0/14 | 1/28 | 0/29 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 0/14 | 0/14 | 0/14 | 0/28 | 1/29 | 0/13 |
Participants who received at least 1 dose of double-blind study drug in DBT phase and OLE phase. Participants in DBT and OLE phases are not exclusive. Eligible participants from DBT phase entered OLE phase after completing treatment in DBT phase.
| Age, Continuous(Years) | DBT: Placebo Then Rimegepant | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant | Total |
|---|---|---|---|---|
| DBT Phase | 57.9 ± 13.05 | 66.2 ± 14.61 | — | 61.9 ± 14.21 |
| OLE Phase | — | — | 61.8 ± 17.83 | 61.8 ± 17.83 |
| Sex: Female, Male(Participants) | DBT: Placebo Then Rimegepant | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant | Total |
|---|---|---|---|---|
| DBT Phase — Female | 11 | 10 | — | 21 |
| DBT Phase — Male | 4 | 4 | — | 8 |
| OLE Phase — Female | — | — | 10 | 10 |
| OLE Phase — Male | — | — | 3 | 3 |
| Ethnicity (NIH/OMB)(Participants) | DBT: Placebo Then Rimegepant | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant | Total |
|---|---|---|---|---|
| DBT Phase — Hispanic or Latino | 3 | 4 | — | 7 |
| DBT Phase — Not Hispanic or Latino | 12 | 10 | — | 22 |
| DBT Phase — Unknown or Not Reported | 0 | 0 | — | 0 |
| OLE Phase — Hispanic or Latino | — | — | 5 | 5 |
| OLE Phase — Not Hispanic or Latino | — | — | 8 | 8 |
| OLE Phase — Unknown or Not Reported | — | — | 0 | 0 |
| Race (NIH/OMB)(Participants) | DBT: Placebo Then Rimegepant | DBT Phase: Rimegepant Then Placebo | OLE Phase: Rimegepant | Total |
|---|---|---|---|---|
| DBT Phase — American Indian or Alaska Native | 0 | 0 | — | 0 |
| DBT Phase — Asian | 0 | 0 | — | 0 |
| DBT Phase — Native Hawaiian or Other Pacific Islander | 0 | 0 | — | 0 |
| DBT Phase — Black or African American | 3 | 1 | — | 4 |
| DBT Phase — White | 12 | 12 | — | 24 |
| DBT Phase — More than one race | 0 | 0 | — | 0 |
| DBT Phase — Unknown or Not Reported | 0 | 1 | — | 1 |
| OLE Phase — American Indian or Alaska Native | — | — | 0 | 0 |
| OLE Phase — Asian | — | — | 0 | 0 |
| OLE Phase — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 |
| OLE Phase — Black or African American | — | — | 2 | 2 |
| OLE Phase — White | — | — | 10 | 10 |
| OLE Phase — More than one race | — | — | 0 | 0 |
| OLE Phase — Unknown or Not Reported | — | — | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2019 to primary completion in May 2023, 46 months.
Results were first posted in Jun 2024, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant